论文部分内容阅读
目的评价EL方案(洛铂联合依托泊苷)治疗初治小细胞肺癌的近期疗效和不良反应。方法选择2011年6月至2013年1月我科收治的56例初治小细胞肺癌患者为研究对象,所有患者均经病理组织学或细胞学确诊,采用EL方案化疗:洛铂30mg/m2静滴,d1;依托泊苷100mg/m2静滴,d1～5,21d为1周期,连续用药2周期以上。参照RECIST1.1和CTCAE-3标准评价近期疗效和不良反应。结果 56例患者中,7例(12.5%)完全缓解,39例(69.6%)部分缓解,治疗总有效率为82.1%,不良反应主要表现为骨髓抑制,III～IV胃肠道反应的发生率仅为3.4%。结论 EL方案治疗初治SCLC的疗效好,主要不良反应为骨髓抑制,胃肠道反应较轻,安全耐受性好。
Objective To evaluate the short-term efficacy and side effects of EL regimen (lobaplatin plus etoposide) in the treatment of primary small cell lung cancer. Methods 56 patients with newly diagnosed small cell lung cancer admitted to our department from June 2011 to January 2013 were enrolled in this study. All patients were diagnosed by histopathology or cytology. EL chemotherapy was given: 30 mg / m 2 Drip, d1; etoposide 100mg / m2 intravenous infusion, d1 ~ 5,21d for 1 cycle, continuous treatment for more than 2 cycles. RECIST1.1 and CTCAE-3 criteria to evaluate the short-term efficacy and adverse reactions. Results Of the 56 patients, 7 (12.5%) were completely relieved and 39 (69.6%) were partially relieved. The total effective rate was 82.1%. Adverse reactions mainly included myelosuppression and the incidence of gastrointestinal reactions III ~ IV Only 3.4%. Conclusion The EL regimen has a good curative effect in the treatment of naive SCLC. The main adverse reactions are myelosuppression, mild gastrointestinal reactions and good safety tolerance.